Anneli Nordqvist

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/396949/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Functionalized 3-amino-imidazo[1,2-a]pyridines: A novel class of drug-like Mycobacterium tuberculosis glutamine synthetase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4790-4793.	2.2	85
2	Virtual screening and bioassay study of novel inhibitors for dengue virus mRNA cap (nucleoside-2′O)-methyltransferase. Bioorganic and Medicinal Chemistry, 2007, 15, 7795-7802.	3.0	72
3	Links between bacterial production, amino-acid utilization and community composition in productive lakes. ISME Journal, 2007, 1, 532-544.	9.8	51
4	Synthesis of Functionalized Cinnamaldehyde Derivatives by an Oxidative Heck Reaction and Their Use as Starting Materials for Preparation ofMycobacterium tuberculosis1-Deoxy-d-xylulose-5-phosphate Reductoisomerase Inhibitors. Journal of Organic Chemistry, 2011, 76, 8986-8998.	3.2	50
5	Evaluation of the amino acid binding site of Mycobacterium tuberculosis glutamine synthetase for drug discovery. Bioorganic and Medicinal Chemistry, 2008, 16, 5501-5513.	3.0	33
6	Synthesis, biological evaluation and X-ray crystallographic studies of imidazo[1,2-a]pyridine-based Mycobacterium tuberculosis glutamine synthetase inhibitors. MedChemComm, 2012, 3, 620.	3.4	29
7	A General Model for Prediction of Caco-2 Cell Permeability. QSAR and Combinatorial Science, 2004, 23, 303-310.	1.4	28
8	Discovery of retinoic acid receptor agonists as proliferators of cardiac progenitor cells through a phenotypic screening approach. Stem Cells Translational Medicine, 2020, 9, 47-60.	3.3	21
9	GPR103 Antagonists Demonstrating Anorexigenic Activity in Vivo: Design and Development of Pyrrolo[2,3- <i>c</i>)pyridines That Mimic the C-Terminal Arg-Phe Motif of QRFP26. Journal of Medicinal Chemistry, 2014, 57, 5935-5948.	6.4	19
10	Phenotypic Screen for Cardiac Regeneration Identifies Molecules with Differential Activity in Human Epicardium-Derived Cells versus Cardiac Fibroblasts. ACS Chemical Biology, 2017, 12, 132-141.	3.4	17
11	Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection. Journal of Medicinal Chemistry, 2019, 62, 1385-1406.	6.4	15
12	Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibition. Communications Biology, 2020, 3, 782.	4.4	15
13	Quantitative Structure–Activity Relationships of Pine Weevil Antifeedants, a Multivariate Approach. Journal of Agricultural and Food Chemistry, 2007, 55, 9365-9372.	5.2	14
14	Structureâ€Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity. ChemMedChem, 2017, 12, 50-65.	3.2	13
15	Neuropeptide 26RFa (QRFP) is a key regulator of glucose homeostasis and its activity is markedly altered in obese/hyperglycemic mice. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E147-E157.	3.5	13
16	Microwave-Enhanced α-Arylation of a Protected Glycine in Water:Evaluation of 3-Phenylglycine Derivatives as Inhibitors of the Tuberculosis Enzyme, Glutamine Synthetase. Combinatorial Chemistry and High Throughput Screening, 2007, 10, 783-789.	1.1	11
17	Structural Characterization of Agonist Binding to Protease-Activated Receptor 2 through Mutagenesis and Computational Modeling. ACS Pharmacology and Translational Science, 2018, 1, 119-133.	4.9	9
18	Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods. Journal of Computer-Aided Molecular Design, 2015, 29, 1109-1122.	2.9	7

#	Article	IF	CITATIONS
19	New Hits as Antagonists of GPR103 Identified by HTS. ACS Medicinal Chemistry Letters, 2014, 5, 527-532.	2.8	6
20	Mineralocorticoid Receptor Antagonists. Vitamins and Hormones, 2019, 109, 151-188.	1.7	5